R&D spending more than doubled to $17.8 million as Corvus pushes soquelitinib into lymphoma, eczema, hidradenitis suppurativa and now asthma, widening the loss past consensus. The $202.9 million cash pile funds operations into the second quarter of 2028, which covers the 2027 readouts that decide this story.
Latest Activity
CRVS Coverage
3 Penny Stocks Wall Street Sees With 243% Upside
Penny stocks captivate investors with their low prices. The allure of controlling large numbers of shares for relatively very little money, and potentially generating explosive gains if their stocks move just a…
Tuesday’s Top Wall Street Upgrades and Downgrades: Applied Materials, CVS Health, Hawaiian Electric Industries, Walmart and More
Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.
5 White-Hot Stocks Trading Under $10 to Buy Now Have Great Upside Potential
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Wednesday Afternoon’s Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More
Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.
Top Analyst Upgrades and Downgrades: Akamai, Avaya, Canopy Growth, Corsair Gaming, Playtika, Virgin Galactic and More
Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Avaya, Canopy Growth, Corsair Gaming, Skyworks Solutions and Virgin Galactic.